Table 1.
General characteristics of participants
| Characteristics | COVID-19 | Control | Total | P value |
|---|---|---|---|---|
| Age (years) | 46 ± 10.2 | 44.6 ± 6.4 | 45.3 ± 9.2 | 0.08 |
| Age of asthma onset (years) | 19.8 | 20.23 | 20.14 | 0.05 |
| Male | 182 (73%) | 128 (51%) | 310 (62%) | |
| Female | 93 (37%) | 97 (39%) | 190 (38%) | |
| Exacerbation required medical attention in the previous 12 months | 40 (16%) | 45 (18%) | 85 (34%) | 0.2 |
| COVID-19 vaccine completion (more than two doses for more than 14 days) | 225 (90%) | 225 (90%) | 450 (90%) | 0.001 |
| Baseline FEV1 (L) | 2.12 ± 0.82 | 2.05 ± 0.7 | 2.08 ±0.75 | 0.3 |
| FEV1 baseline (percent predicted) | 89.2 ± 23.5 | 91.8 ± 12.4 | 90.11 ± 34 | 0.5 |
| Baseline FVC (L) | 3.12 ± 1.3 | 3.23 ± 0.67 | 3.18 ± 98 | 0.8 |
| Baseline FVC (percent predicted) | 104.5 ± 12.3 | 117.4 ± 66.3 | 11.9 ± 39.2 | 0.3 |
| Baseline FEV1/FVC | 65.8 ± 26.9 | 67.4 ± 84.7 | 66.6 ± 5.8 | 0.6 |
| ACT score at the previous visit | 20.0 ± 1.2 | 20.0 ± 4.7 | 20.0 ± 2.4 | 0.7 |
| ACT score at enrollment | 16.8 ± 3.9 | 20.0 ± 3.2 | 18.4 ± 4.3 | <0.0001 |
| Asthma control at the most recent visit based on ACT score | ||||
| Controlled | 130 (52%) | 154 (58%) | 284 (56.8%) | |
| Partially controlled | 75 (30%) | 85 (34%) | 160 (32%) | |
| Uncontrolled | 45 (18%) | 11 (8%) | 56 (11%) | |
| Asthma control at enrollment based on ACT score | 95 (38%) | 120 (48%) | 215 (43%) | |
| Partially controlled | 50 (10%) | 110 (22%) | 160 (32%) | |
| Uncontrolled | 115 (28%) | 10 (2%) | 125 (25%) | |
| Escalation of asthma treatment | 205 (41%) | 125 (25%) | 330 (66%) | |